Private Companies 12

SWITZ

October 17, 2017: Covagen AG issued new U.S. patent [9,790,475]

NEWS BITES - PRIVATE COMPANIES

Covagen AG has been issued a new U.S. patent titled "Human serum albumin binding compounds and fusion proteins thereof" by the US Patent and Trademark Office.

ABSTRACT

The present invention relates to a polypeptide binding to human serum albumin and comprising or consisting of an amino acid sequence selected from the group consisting of: (a) GVTLFVALYDY(X.sup.1)(X.sup.2)(X.sup.3)(X.sup.4)(X.sup.5) (X.sup.6)D(X.sup.7)SFHKGEKFQIL(X.sup.8)(X.sup.9)(X.sup.10)(X.sup.11)(X.su- p.12)G(X.sup.13)(X.sup.14)W(X.sup.15)(X.sup.16)RSLTTG(X.sup.17)(X.sup.18)G- (X.sup.19)IPSNYVAPVDSIQ (SEQ ID NO: 1), wherein (X.sup.1) is A, V, I, L, M, G, P, S, T, N, Q, C, R, H, K, D or E; (X.sup.2) is R, H, K, A, V, I, L, M, G, P, S, T, N, Q or C; (X.sup.3) is R, H, K, S, T, N, Q, C, F, Y, W, A, V, I, L, M, G or P; (X.sup.4) is S, T, N, Q, C, A, V, I, L, M, G, P, R, H, K, F, Y, W, D or E; (X.sup.5) is S, T, N, Q, C, D, E, F, Y, W, A, V, I, L, M, G, P, R, H or K; (X.sup.6) is F, Y, W, A, V, I, L, M, G, P, R, H, K, S, T, N, Q or C; (X.sup.7) is A, V, I, L, M, G, P, R, H or K; (X.sup.8) is S, T, N, Q, C, D or E; (X.sup.9) is S, T, N, Q, C, D, E, A, V, I, L, M, G, P, F, Y or W; (X.sup.10) is A, V, I, L, M, G or P; (X.sup.11) is F, Y, W, R, H or K; (X.sup.12) is S, T, N, Q, C, F, Y or W; (X.sup.13) is F, Y, W, R, H, K, S, T, N, Q, C, D, E, A, V, I, L, M, G or P; (X.sup.14) is F, Y, W, A, V, I, L, M, G or P; (X.sup.15) is D, E, A, V, I, L, M, G or P; (X.sup.16) is A, V, I, L, M, G or P; (X.sup.17) is D, E, A, V, I, L, M, G, P, R, H or K; (X.sup.18) is S, T, N, Q, C, A, V, I, L, M, G or P; (X.sup.19) is F, Y, W, S, T, N, Q or C; and (b) an amino acid sequence which is at least 90% identical to the amino acid sequence of (a), wherein the identity determination excludes amino acid positions (X.sup.1) to (X.sup.19).

Appl. No.14/758,339
PCT FiledDecember 18, 2013
PCT No.PCT/EP2013/077227

INDEX

SECTION 1 COVAGEN AG PROFILE

SECTION 2 OTHER NEWS: 2014

SECTION 3 COVAGEN AG PATENTS

SECTION 4 COVAGEN AG TOP MANAGEMENT

SECTION 1 COVAGEN AG PROFILE

1.1 ACTIVITIES

Covagen AG develops protein therapeutics/drugs for the treatment of inflammatory diseases and cancer. Its platform technology enables the isolation of high affinity protein-based binders called fynomers, which change the activity of target molecules relevant in various diseases. Covagen AG has strategic research collaborations and license agreements with Mitsubishi Tanabe Pharma Corporation and Tanabe Research Laboratories U.S.A., Inc. The company was founded in 2007 and is based in Zurich, Switzerland.

1.2 SUMMARY

PermID: 5000445316

Website: http://www.covagen.com

SECTION 2 OTHER NEWS: 2014

May 05: Covagen Initiates Phase Ib/IIa Study of Bispecific anti-TNF/IL-17A FynomAb COVA322

[Company Release]

Covagen today announced it has initiated a Phase Ib/IIa study with COVA322, a bispecific TNF/IL-17A inhibitor. COVA322 is Covagen's lead bispecific FynomAb(Registered) developed for treatment of patients with rheumatoid arthritis, psoriatic arthritis and other inflammatory diseases. The trial will enroll 39 patients with psoriasis and evaluate safety as well as biological activity of COVA322. Enrollment in the trial and dosing of COVA322 has begun for the first cohort of patients.

"With COVA322, Covagen has moved its first proprietary FynomAb into the clinic," said Mathias Locher, Ph.D., chief development officer of Covagen. "COVA322 has a novel mechanism of action by simultaneously inhibiting both TNF and IL-17A. This dual inhibition has the potential to result in superior efficacy compared to current treatment options for rheumatoid arthritis, psoriatic arthritis and other inflammatory diseases."

Julian Bertschinger, Ph.D., chief executive officer of Covagen added: "We believe this first clinical study with COVA322 in psoriasis patients may indicate its significant potential to improve the treatment of inflammatory diseases and help to validate the capabilities of our proprietary bispecific FynomAb platform.

SECTION 3 COVAGEN AG PATENTS

PREVIOUS PATENT STORY:

March 14, 2017 Covagen AG issued new U.S. patent [9,593,314]

ABSTRACT

The present invention relates to a binding molecule that specifically binds to two different epitopes of an antigen expressed on tumor cells, wherein the binding molecule comprises: (a) a first binding (poly)peptide that specifically binds to a first epitope of said antigen expressed on tumor cells, wherein said first binding (poly)peptide is a Fyn SH3-derived polypeptide; and (b) a second binding (poly)peptide that specifically binds to a second epitope of said antigen expressed on tumor cells. The present invention further relates to a nucleic acid molecule encoding the binding molecule of the invention, a vector comprising said nucleic acid molecule as well as a host cell or a non-human host transformed with said vector. The invention further relates to a method of producing a binding molecule of the invention as well as to pharmaceutical and diagnostic composition. Moreover, the present invention also relates to the binding molecule, the nucleic acid molecule, the vector or the host cell of the invention for use in the treatment of tumors.

SECTION 4 COVAGEN AG TOP MANAGEMENT

Dr. Julian Bertschinger, CEO

Julian Bertschinger co-invented Covalent DNA technology as a Ph.D. student in the group of Prof. Dario Neri at the Institute of Pharmaceutical Sciences ETH Zurich. After further development of the technology while a postdoctoral fellow in Prof. Neri's group, Julian Bertschinger was selected in June 2006 from more than 100 applicants as one of the winners of the Venture Leaders Prize founded by the Gebert Ruf Stiftung. The prize enabled him to join a training program at Babson College in the Boston area with a course in entrepreneurship. Julian Bertschinger co-founded Covagen in 2007 and has been Covagen's CEO since its foundation

Dr. Karl Nagler, Chairman

Karl Nagler joined Gimv in 2011 as partner and works out of Gimv's Munich office. Prior to joining Gimv he worked as General Partner with Ventech, a Paris-based Europe and China focused VC fund where he led investments into Funxional Therapeutics (acquired by Boehringer Ingelheim), Themis and Prosonix and served on the boards of those companies.

 Karl Nagler started his professional career between 2002 and 2009 at Atlas Venture (London and Munich), a transatlantic venture fund where he was instrumental in the formation and/or financing of several start-ups across Europe, including U3 Pharma (acquired by Daiichi Sankyo) and Nitec Pharma (acquired by Horizon Pharma). Previously, he worked as a Scientific Fellow at the CNRS for Neurochemistry in Strasbourg (France).

 Karl Nagler holds a Ph.D. in molecular neurobiology from the Max-Delbruck-Center for Molecular Medicine (Berlin) and a diploma in Biology from the Free University of Berlin.

PermID: 5000445316

Created by www.buysellsignals.com for News Bites Finance